ra-9

RA-9 is a potent and selective proteasome-associated inhibitor of deubiquitinating enzymes (DUBs) with a favorable toxicity profile and anticancer activity, particularly effective in inducing apoptosis in ovarian cancer cell lines.

Ginsenoside Ra9 is a rare and recently identified protopanaxadiol-type triterpene saponin isolated from Asian ginseng (Panax ginseng), distinguished by unique butenoyl and acetyl sugar modifications on the dammarane core structure that confer reduced polarity characteristic of Ra-type ginsenosides, and making it a valuable subject for advanced pharmacological, metabolic, and natural product research studies.

1-bromo-5-hydroxyanthra-9,10-quinone is a useful organic compound for research related to life sciences and the catalog number is T131407.

ent-17-Hydroxykaura-9(11),15-dien-19-oic acid is a natural product from Wedelia trilobata.

neuropeptide Y Y5 receptor antagonist

KIRA9 is a potent inhibitor of IRE1 with an IC50 value of 4.8 μM for INS-1 cells. KIRA9 completely binds the ATP binding site of IRE1 and blocks endoplasmic reticulum (ER) localised mRNA decay and apoptosis.

2,3,5,6-Tetra(9H-carbazol-9-yl)terephthalonitrile is a useful organic compound for research related to life sciences and the catalog number is T64401.

2,4,5,6-Tetra(9H-carbazol-9-yl)-1,3-Dicyanobenzene is a useful organic compound for research related to life sciences. The catalog number is T64416 and the CAS number is 1416881-52-1.

SS148 is an nsp14/nsp16 MTase inhibitor. It also showed some degree of selectivity against human protein MTases, an indication of great potential for chemical optimization towards more potent and selective inhibitors of coronavirus MTases.

Atorvastatin ethyl ester, a derivative of Atorvastatin, exhibits potent inhibition of 9-cis-RA-induced Gal4 reporter activity.

Atorvastatin methyl ester is a derivative of Atorvastatin. It inhibits the 9-cis-RA-induced Gal4 reporter activity more strongly than Atorvastatin.

Tarenflurbil ((R)-Flurbiprofen) is the non-cyclooxygenase inhibiting R-enantiomer of the NSAID flurbiprofen, evaluated as a treatment for Alzheimer's disease.

AGN 193109 is a potent antagonist of retinoic acid receptors (RARs; Kd= 2, 2, and 3 nM for RARα, β, and γ, respectively), exhibiting selectivity for RARs over retinoid X receptors (RXRs; Kd= >10,000 nM for human RXRα, β, and γ receptors). This compound effectively reverses cellular morphology changes and growth suppression induced by RAR agonists such as all-trans-RA, 13-cis-RA, and 9-cis-RA in ECE16-1 human endometrial ectocervical epithelial cells, particularly when used at a 10-fold molar excess. Furthermore, AGN 193109 downregulates the expression of cytokeratin K5-8, 13, 14, 16, 17, and 19 genes, indicating inhibition of retinoid action, specifically when co-administered with TTNPB but not as a standalone treatment. In vivo studies demonstrate teratogenic effects, including cleft palate, frontonasal dysplasia, and eye malformations in mouse fetuses following a single oral dose of 1 mg/kg.